Exelixis (EXEL) 8/7/12
$225m (+33.75m) REG unsec sen sub cb pricing wed nite from GS. Terms: 7yr, 3.75-4.25% up 25-30%, nc-4, 130% after, prot. UOP = GCP. Concurrent offering of 20m shares. Biotech co focused on developing small-molecule therapies for cancer treatment. Key drug = CABO. FDA approval likely for thyroid cancer version in Nov, but mkt is small. CRPC version is crucial, but phase 3 trials not expected til 1H2014. Expected cash burn thru 2015 could see some sort of partnership down the road. We’ll use L+1050. Not really a vol trade but for modeling, we’ll use 38 vol. Brw is 150 bps. Theo = 96.5/98.5/100.75. Small deal, hot sector, should be one for strong equity interest, but with lack of short term catalysts we’d be selective and BUY on cheaps.